Slide 1: Q2 2026 Earnings Call
Q2 2026 Earnings Call August 11, 2026
Slide 2: Safe harbor disclosures
Safe harbor disclosures Forward Looking Statements The forward-looking statements in this presentation are made only as of the date hereof. For a further Certain statements in this presentation and the accompanying oral commentary are forward-looking description of the risks and uncertainties that c
Slide 3: Growing evidence base driving increasing Proteograph adoption
Growing evidence base driving increasing Proteograph adoption Growing external validation Researchers are makes us a trusted partner Cumulative peer-reviewed demonstrating differentiated publications Proteograph insights 95 customer publications, ASMS 2026 2026 preprints and reviews1 95 • Seer & Kor
Slide 4: Independent head-to-head comparison from Roche published in Journal of Proteome Research
Independent head-to-head comparison from Roche published in Journal of Proteome Research evaluated six leading plasma proteomics workflows Examined biological origin, robustness, and signal interpretability, and concluded that nanoparticle enrichment delivers substantially deeper plasma proteome cov
Slide 5: Nature Genetics authors leveraged the Proteograph to identify links between genetic variants and disease risk
Nature Genetics authors leveraged the Proteograph to identify links between genetic variants, plasma protein levels and disease risk Compared Seer’s Proteograph platform against two affinity-based assays, Olink HT and SomaLogic 11k, in a study of roughly 1,400 individuals of British South Asian ance
Slide 6: Furthering the adoption of proteomics by enabling deep, unbiased population-scale studies
Furthering the adoption of proteomics by enabling deep, unbiased population-scale studies 10,000-sample study secured in collaboration with Precision Health Research, Singapore Large-scale multiomics study funded by the NIH 10,000-sample study secured in collaboration with Discovery Life Sciences 20
Slide 7: Q2 2026 financial overview
Q2 2026 financial overview Q2’26 Q2’25 Revenue $3.1M $4.1M Product Revenue Service Revenue $2.3M $0.7M $2.7M $0.8M ~$209.5M Cash, cash equivalents and Related Party Revenue - $0.4M investments, no debt1 Other Revenue $0.1M $0.1M Gross Margin 49% 52% ~0.2M Operating Expenses $18.3M $22.6M shares Stoc
Slide 8: Reiterating full year 2026 revenue guidance
Reiterating full year 2026 revenue guidance $16M - $18M ~3% y/y growth at midpoint 8
Slide 9: 2026 growth catalysts
2026 growth catalysts Expand addressable Win additional market through new population-scale product innovation cohort programs Revenue growth Establish leadership Grow and drive utilization position as preferred of rapidly expanding proteomic data platform installed base for AI-driven biology 9 © 20
Slide 10: Slide 10